<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25003" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mercaptopurine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Hala</given-names>
          </name>
          <aff>Poznan University of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hala Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25003.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Mercaptopurine is a medication used in the management and treatment of acute lymphoblastic leukemia. It is in the class of medications known as purine antagonists. This activity reviews the indications, action, and contraindications for mercaptopurine as a valuable agent in treating and managing leukemias and inflammatory autoimmune disorders. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with acute lymphoblastic leukemia and some inflammatory autoimmune-related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of mercaptopurine.</p></list-item><list-item><p>Describe the potential adverse effects of mercaptopurine.</p></list-item><list-item><p>Review the appropriate monitoring for patients on mercaptopurine.</p></list-item><list-item><p>Summarize the interprofessional team strategies for improving care coordination and communication to advance mercaptopurine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25003&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25003">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25003.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Mercaptopurine (6MP) was approved by the Food and Drug Administration (FDA) for use in acute lymphoblastic leukemia in children and adults as part of combination therapy. However, there are several off-label uses for 6MP<xref ref-type="bibr" rid="article-25003.r1">[1]</xref><xref ref-type="bibr" rid="article-25003.r2">[2]</xref><xref ref-type="bibr" rid="article-25003.r3">[3]</xref><xref ref-type="bibr" rid="article-25003.r4">[4]</xref><xref ref-type="bibr" rid="article-25003.r5">[5]</xref>:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Maintenance treatment in childhood acute promyelocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Lymphoblastic lymphoma</p>
          </list-item>
          <list-item>
            <p>Crohn disease management after surgical resection or as a steroid-sparing therapy</p>
          </list-item>
          <list-item>
            <p>Induction and remission maintenance in ulcerative colitis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus (SLE)</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Childhood severe atopic eczema</p>
          </list-item>
          <list-item>
            <p>Treating autoimmune hepatitis in children</p>
          </list-item>
          <list-item>
            <p>Preventing tissue rejection after organ transplantation</p>
          </list-item>
          <list-item>
            <p>Other dermatological conditions</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25003.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mercaptopurine and azathioprine&#x000a0;are&#x000a0;prodrugs of a purine analog hypoxanthine that works as an antagonist to endogenous purines required for DNA replication during the S-phase of the cell cycle and inhibition of RNA and protein synthesis. Azathioprine breaks down into 88% mercaptopurine and 12% other thiopurine metabolites. 6MP&#x000a0;requires conversion into 6-thioguanine nucleotides (6TGN) to become active and exert antileukemic effects.<xref ref-type="bibr" rid="article-25003.r6">[6]</xref></p>
        <p>The prodrug is metabolized in the liver, GI tract and taken up by lymphocytes, where mercaptopurine is metabolized via the purine salvage enzyme via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to thioguanine nucleotides 6TGN and thioinosine monophosphate (TIMP). Inosine triphosphate (ITPA) catalyzes the hydrolysis of thioinosine triphosphate (TITP) to thioinosine monophosphate (TIMP), which increases 6TGN levels.<xref ref-type="bibr" rid="article-25003.r7">[7]</xref></p>
        <p>There is also a secondary pathway&#x000a0;via thiopurine methyltransferase (TPMT),&#x000a0;which produces&#x000a0;inactive methylated bases, 6-methylmercaptopurine. The methylated metabolite, methyl-thioinosine monophosphate (Me-TIMP), is a potent inhibitor of the purine de novo synthesis. Me-TIMP further reduces purines available for incorporation in DNA synthesis.<xref ref-type="bibr" rid="article-25003.r7">[7]</xref></p>
        <p>Deoxy-6-thioguanine triphosphate (6-dTGTP) incorporates into DNA, and 6-thioguanine triphosphate (6-TGTP) inserts into RNA.&#x000a0;6-TGTP also binds to Rac1, resulting in the inactivation of the Vav-Rac1 signaling pathway in T-lymphocytes. This process further prevents the activation of Rac1 target genes such as nuclear factor kappa beta (NF-kB), which induces apoptosis of activated T-lymphocytes.<xref ref-type="bibr" rid="article-25003.r6">[6]</xref></p>
        <p>The replacement of the endogenous purines with these synthetic thiopurine nucleotides&#x000a0;results in purine deprivation within the cells,&#x000a0;which halts&#x000a0;DNA, RNA, and protein synthesis leading to decreased cell proliferation and cytotoxicity.<xref ref-type="bibr" rid="article-25003.r8">[8]</xref><xref ref-type="bibr" rid="article-25003.r9">[9]</xref><xref ref-type="bibr" rid="article-25003.r10">[10]</xref></p>
      </sec>
      <sec id="article-25003.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Mercaptopurine comes as a 50 mg tablet that may be administered orally as either a tablet or suspension, preferably on an empty stomach at the same time each day.<xref ref-type="bibr" rid="article-25003.r11">[11]</xref>&#x000a0;The dosage varies from 1&#x000a0;to 3 mg/kg or 50&#x000a0;to 150 mg/day for long-term therapy.<xref ref-type="bibr" rid="article-25003.r12">[12]</xref>&#x000a0;The therapeutic response is generally observable after three months of therapy, but it may take longer to observe results.&#x000a0;Dosages may need to be adjusted based on the patient's renal or hepatic impairments.&#x000a0;</p>
      </sec>
      <sec id="article-25003.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Patients may exhibit non-dose dependent or dose-dependent side effects while undergoing treatment with mercaptopurine. Allergic reactions such as nausea, fever, rash, flu-like symptoms, and arthralgias are considered non-dose-dependent symptoms that may require changing the timing of dosing to night-time administration or discontinuation of therapy.<xref ref-type="bibr" rid="article-25003.r13">[13]</xref></p>
        <p>These symptoms may also reoccur in patients reintroduced to azathioprine or mercaptopurine after an initial adverse reaction.&#x000a0;<xref ref-type="bibr" rid="article-25003.r14">[14]</xref>&#x000a0;To reduce these symptoms, administering 6MP at night may be required.<xref ref-type="bibr" rid="article-25003.r13">[13]</xref></p>
        <p>Dose-dependent adverse reactions that are potentially observable with 6MP are<xref ref-type="bibr" rid="article-25003.r13">[13]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Jaundice&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pancreatitis (3.3%)</p>
          </list-item>
          <list-item>
            <p>Myelosuppression (2&#x000a0;to 15%)</p>
          </list-item>
          <list-item>
            <p>Elevation of transaminases (30%)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drug hepatitis (0.3%)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Nodular regenerative hyperplasia and veno-occlusive disease</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Myelosuppression with high levels of 6TGN (2&#x000a0;to 15%)</p>
          </list-item>
          <list-item>
            <p>EB virus-positive lymphoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatosplenic T-cell lymphoma (HSTCL)</p>
          </list-item>
        </list>
        <p>There are various forms of hepatotoxicity resulting from both acute and chronic mercaptopurine intake. Acute liver injury is usually observed as elevated liver enzymes with fatigue and jaundice within one to six months after starting therapy. The liver biopsy depicts mixed hepatocellular-cholestatic injury with cholestasis, focal hepatocellular necrosis, bile duct injury, and variable inflammation.<xref ref-type="bibr" rid="article-25003.r12">[12]</xref></p>
        <p>In chronic therapy, nodular regenerative hyperplasia (NRH) and symptomatic portal hypertension with ascites and varices were observed from six months to several years after starting therapy. This condition physically presented itself in patients as ascites, varices, mild liver enzyme abnormalities, and jaundice. It is a cause of concern because it can progress to hepatic failure if 6MP therapy is not discontinued.<xref ref-type="bibr" rid="article-25003.r15">[15]</xref><xref ref-type="bibr" rid="article-25003.r12">[12]</xref></p>
        <p>Hepatosplenic T-cell lymphoma (HSTCL) is a rare complication with a high mortality rate reported in men with inflammatory bowel disease who have been immunosuppressed long term with thiopurines such as mercaptopurine with or without anti-tumor necrosis factor therapy. They present with fatigue, fever, hepatosplenomegaly, and pancytopenia. Diagnosis is from either bone marrow or liver biopsy showing marked infiltration with malignant T cells.<xref ref-type="bibr" rid="article-25003.r12">[12]</xref></p>
        <p>Also,&#x000a0;<italic toggle="yes">NUDT15</italic>&#x000a0;correlates with thiopurine-induced myelosuppression.<xref ref-type="bibr" rid="article-25003.r16">[16]</xref>&#x000a0;</p>
        <p>It is important to note that switching from 6MP to AZA does not reduce the risk of side effects.<xref ref-type="bibr" rid="article-25003.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25003.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>If patients are previously known to have severe allergic or hypersensitivity reactions, they are required to discontinue the use of the medication immediately. Mercaptopurine&#x000a0;is also contraindicated for use in patients who have previously shown resistance to the drug.</p>
        <p>There should be at least a two-month window between the cessation of mercaptopurine treatment and vaccination with live viral or bacterial vaccines to prevent severe and fatal infections.<xref ref-type="bibr" rid="article-25003.r18">[18]</xref>&#x000a0;Approximately 2 to 4% of patients receiving treatment with thiopurines develop thiopurine-induced pancreatitis. This condition is an absolute contraindication to the reintroduction of thiopurines.<xref ref-type="bibr" rid="article-25003.r19">[19]</xref></p>
      </sec>
      <sec id="article-25003.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>All patients require complete blood count and liver enzymes every two weeks for six to eight weeks since starting azathioprine or mercaptopurine treatment. The testing should be followed by changes or adjustments in treatment as well.<xref ref-type="bibr" rid="article-25003.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Monitoring 6TG level concentrations to be maintained between 230 and 400 proves to be related to sufficient bone marrow suppression and reduces the chances of liver toxicity.<xref ref-type="bibr" rid="article-25003.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Research has found some medications to increase mercaptopurine levels in the plasma. Allopurinol and febuxostat inhibit the first-pass metabolism of 6MP via enzyme xanthine oxidase (XO), which resulted in a fivefold increase in plasma 6MP concentrations and a threefold increase in steady-state erythrocyte 6-TGN concentrations.<xref ref-type="bibr" rid="article-25003.r22">[22]</xref>&#x000a0;This effect may be useful in inducing shunting of 6MMP metabolites towards 6TG in patients with 6MP resistance.<xref ref-type="bibr" rid="article-25003.r23">[23]</xref><xref ref-type="bibr" rid="article-25003.r24">[24]</xref><xref ref-type="bibr" rid="article-25003.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Methotrexate can also increase 6MP plasma levels by forming active metabolites via XO inhibition and other mechanisms.<xref ref-type="bibr" rid="article-25003.r22">[22]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with IBD, vigilant monitoring of CBC counts is necessary when receiving combined therapy that includes mercaptopurine. 5-aminosalicylates cause in vitro inhibition of TPMT. Combining 6MP with mesalazine or sulfasalazine induced mild to moderate leukopenia.<xref ref-type="bibr" rid="article-25003.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent treatment of warfarin while being treated with 6MP is known to diminish the anticoagulant effects. Also, discontinuing 6MP with an adjusted warfarin dose can lead to bleeding in a previously stable patient.<xref ref-type="bibr" rid="article-25003.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>NSAIDs such as naproxen, mefenamic acid, tolfenamic acid exhibit noncompetitive inhibition of TPMT activity in vitro and thus require monitoring while the patient receives treatment with mercaptopurine.<xref ref-type="bibr" rid="article-25003.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Mercaptopurine therapy should be&#x000a0;reduced by 50% of the current dose or discontinued if the patient exhibits leukopenia (WBC =&#x0003c; 4000 cells/mm^3) or thrombocytopenia (platelet count &#x0003c; 150,000/microL). If the patient continues to show persistent cytopenia with the dosage reduction, the medication should be permanently discontinued.<xref ref-type="bibr" rid="article-25003.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>If mild hepatitis (transaminitis) is present, it is reversible by lowering the dose of 6MP. If ALT and AST levels continue to remain elevated, a further dose reduction by 33&#x000a0;to 50% will be necessary. Liver function tests require monitoring and evaluation every two weeks. ALT and AST levels should not exceed two times the upper limit of normal. If such an event occurs, the medication should be discontinued until the liver enzyme levels normalize, at which point 6MP may be reintroduced cautiously at a lower dose.<xref ref-type="bibr" rid="article-25003.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Macrocytosis should have close monitoring, with CBC every two weeks for one month to exclude other causes such as vitamin B12 or folate deficiencies.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mercaptopurine may be used during pregnancy with close monitoring. There is no known risk of teratogenicity or higher rates of pregnancy complications with the use of this medication. Concentrations of 6MP have not been detected in breast milk.<xref ref-type="bibr" rid="article-25003.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25003.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>It is important to maintain a constant dose titration to maintain steady thiopurine exposure while minimizing toxicity. There have been observations that in patients with nonfunctional variant alleles of TPMT or with reduced TPMT enzyme activity, there is a resulting accumulation of 6TGN in hematopoietic tissues causing toxicity.<xref ref-type="bibr" rid="article-25003.r16">[16]</xref></p>
      </sec>
      <sec id="article-25003.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to its narrow therapeutic index, mercaptopurine requires continuous monitoring for toxicity in patients due to enzyme activity levels and interactions with other medications. This medication is listed in the Institute for Safe Medication Practices (ISMP),&#x000a0;where it is among&#x000a0;a list of drugs classified&#x000a0;as having a heightened risk of causing significant patient harm when used in error. Because 6MP is a maintenance treatment for inflammatory disorders and leukemia with other disease-modifying agents or chemotherapy, adjustments may be needed frequently or intermittently throughout the time of administration.&#x000a0;</p>
        <p>Most, if. not all, of the diseases that require mercaptopurine therapy are chronic conditions requiring long-term treatment.&#x000a0;Pharmacists need to ensure that dosage levels are appropriately administered based on side effects and contraindications. The patients will require both inpatient and at-home care throughout the course of their treatment. Also, to ensure the efficacy of the treatment, patient compliance will need to be taken into account because this is a slow-acting medication. This level of monitoring requires the actions of an interprofessional team,&#x000a0;with coordinated activity and communication&#x000a0;between specialists, general practitioners, mid-level practitioners, nurses, pharmacists, and care staff involved in the patient's care. There is also a long-term risk of secondary leukemia or malignancies occurring with mercaptopurine therapy, which will require follow-up and screening among patients undergoing such treatment.<xref ref-type="bibr" rid="article-25003.r29">[29]</xref> [Level 3]</p>
      </sec>
      <sec id="article-25003.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25003&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25003">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25003/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25003">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25003.s11">
        <title>References</title>
        <ref id="article-25003.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Coburn</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Nayyar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Koliani-Pace</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>527</fpage>
            <page-range>527-533</page-range>
            <pub-id pub-id-type="pmid">31990422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veerman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>H&#x000e4;hlen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamps</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Van Leeuwen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>De Vaan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Solbu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Wering</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Van der Does-Van der Berg</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>911</fpage>
            <page-range>911-8</page-range>
            <pub-id pub-id-type="pmid">8622039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carmona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>J</given-names>
              </name>
              <collab>Guideline Committee</collab>
            </person-group>
            <article-title>Management of Crohn's disease: summary of updated NICE guidance.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>367</volume>
            <fpage>l5940</fpage>
            <pub-id pub-id-type="pmid">31676715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratt</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Flavin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine.</article-title>
            <source>Gastroenterology</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>271</fpage>
            <page-range>271-4</page-range>
            <pub-id pub-id-type="pmid">8536867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mason</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Thioguanine for refractory psoriasis: a 4-year experience.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-72</page-range>
            <pub-id pub-id-type="pmid">11148479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moon</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in&#x000a0;inflammatory bowel disease.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>863</fpage>
            <page-range>863-883</page-range>
            <pub-id pub-id-type="pmid">26876431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerbek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ebbesen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nersting</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frandsen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Appell</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Schmiegelow</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Role of TPMT and ITPA variants in mercaptopurine disposition.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>579</fpage>
            <page-range>579-586</page-range>
            <pub-id pub-id-type="pmid">29387964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dervieux</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sandlund</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Boyett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Relling</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Aug</month>
            <day>15</day>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>1240</fpage>
            <page-range>1240-7</page-range>
            <pub-id pub-id-type="pmid">12149204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dervieux</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Krynetski</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Vanin</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Roussel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Relling</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.</article-title>
            <source>Cancer Res</source>
            <year>2001</year>
            <month>Aug</month>
            <day>01</day>
            <volume>61</volume>
            <issue>15</issue>
            <fpage>5810</fpage>
            <page-range>5810-6</page-range>
            <pub-id pub-id-type="pmid">11479220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wojtuszkiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barcelos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dubbelman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Abreu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000f6;kkerink</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>de Haas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de Groot-Kruseman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaspers</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Cloos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.</article-title>
            <source>Nucleosides Nucleotides Nucleic Acids</source>
            <year>2014</year>
            <volume>33</volume>
            <issue>4-6</issue>
            <fpage>422</fpage>
            <page-range>422-33</page-range>
            <pub-id pub-id-type="pmid">24940700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostrom</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sensel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sather</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Gaynon</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>La</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdmann</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heerema</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Provisor</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Trigg</surname>
                <given-names>ME</given-names>
              </name>
              <collab>Children's Cancer Group</collab>
            </person-group>
            <article-title>Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>May</month>
            <day>15</day>
            <volume>101</volume>
            <issue>10</issue>
            <fpage>3809</fpage>
            <page-range>3809-17</page-range>
            <pub-id pub-id-type="pmid">12531809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Mercaptopurine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>8</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">31643863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahasranaman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology and pharmacogenetics of thiopurines.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>753</fpage>
            <page-range>753-67</page-range>
            <pub-id pub-id-type="pmid">18506437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marinaki</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Arenas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sumi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shobowale-Bakre</surname>
                <given-names>el-M</given-names>
              </name>
              <name>
                <surname>Escuredo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fairbanks</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Sanderson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).</article-title>
            <source>Pharmacogenetics</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-7</page-range>
            <pub-id pub-id-type="pmid">15167706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayoumy</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Simsek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seinen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>CJJ</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>De Boer</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-123</page-range>
            <pub-id pub-id-type="pmid">32090622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.</article-title>
            <source>Cancer Res Treat</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>823</fpage>
            <page-range>823-834</page-range>
            <pub-id pub-id-type="pmid">28882023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korelitz</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Zlatanic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-4</page-range>
            <pub-id pub-id-type="pmid">10372932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Glatstein</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma.</article-title>
            <source>JAMA</source>
            <year>1966</year>
            <month>Nov</month>
            <day>14</day>
            <volume>198</volume>
            <issue>7</issue>
            <fpage>737</fpage>
            <page-range>737-40</page-range>
            <pub-id pub-id-type="pmid">5953328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kennedy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rhatigan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arnott</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Shand</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Satsangi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1255</fpage>
            <page-range>1255-66</page-range>
            <pub-id pub-id-type="pmid">24117596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tremaine</surname>
                <given-names>W</given-names>
              </name>
              <collab>American Gastroenterological Association</collab>
            </person-group>
            <article-title>American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.</article-title>
            <source>Gastroenterology</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>935</fpage>
            <page-range>935-9</page-range>
            <pub-id pub-id-type="pmid">16530531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubinsky</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lamothe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Targan</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sinnett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;or&#x000ea;t</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.</article-title>
            <source>Gastroenterology</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>705</fpage>
            <page-range>705-13</page-range>
            <pub-id pub-id-type="pmid">10734022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grygiel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Monks</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Poplack</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion.</article-title>
            <source>Biochem Pharmacol</source>
            <year>1984</year>
            <month>Dec</month>
            <day>15</day>
            <volume>33</volume>
            <issue>24</issue>
            <fpage>4089</fpage>
            <page-range>4089-92</page-range>
            <pub-id pub-id-type="pmid">6594999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparrow</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hande</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2005</year>
            <month>Sep</month>
            <day>01</day>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>441</fpage>
            <page-range>441-6</page-range>
            <pub-id pub-id-type="pmid">16128682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparrow</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hande</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-14</page-range>
            <pub-id pub-id-type="pmid">17296529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahhal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.</article-title>
            <source>Inflamm Bowel Dis</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1678</fpage>
            <page-range>1678-82</page-range>
            <pub-id pub-id-type="pmid">18521913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilissen</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Bierau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Derijks</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Hooymans</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>van Gennip</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stockbr&#x000fc;gger</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2005</year>
            <month>Oct</month>
            <day>01</day>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>605</fpage>
            <page-range>605-11</page-range>
            <pub-id pub-id-type="pmid">16181300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review.</article-title>
            <source>Am J Geriatr Pharmacother</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-7</page-range>
            <pub-id pub-id-type="pmid">16730624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuffari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bayless</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.</article-title>
            <source>Gut</source>
            <year>2001</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>642</fpage>
            <page-range>642-6</page-range>
            <pub-id pub-id-type="pmid">11302961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25003.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korelitz</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.</article-title>
            <source>World J Gastroenterol</source>
            <year>2013</year>
            <month>May</month>
            <day>28</day>
            <volume>19</volume>
            <issue>20</issue>
            <fpage>2979</fpage>
            <page-range>2979-84</page-range>
            <pub-id pub-id-type="pmid">23716977</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
